Besides Galunisertib and Bintrafusp alfa, two TGF-β neutralizing antibodies are currently under evaluation in two independent ongoing clinical trials (NCT03192345 and NCT02947165) in combination with immune checkpoint inhibitors in HCC (Table 3). Here, TGFB1 is linked to hepatocellular carcinoma.